MiNK Therapeutics, Inc. engages in the discovery, development, and commercialization of allogeneic,off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate, AGENT-797, is in Phase 1 clinical trials.